Epithelial-to-mesenchymal transition in tumor progression

The epithelial-to-mesenchymal transition (EMT) is a biological process in which a non-motile epithelial cell changes to a mesenchymal state with invasive capacities. However, the EMT program is involved in both physiological and pathological processes. Cancer-associated EMT is known to contribute to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical oncology (Northwood, London, England) London, England), 2017-07, Vol.34 (7), p.122-122, Article 122
Hauptverfasser: Prieto-García, Elena, Díaz-García, C. Vanesa, García-Ruiz, Inmaculada, Agulló-Ortuño, M. Teresa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 122
container_issue 7
container_start_page 122
container_title Medical oncology (Northwood, London, England)
container_volume 34
creator Prieto-García, Elena
Díaz-García, C. Vanesa
García-Ruiz, Inmaculada
Agulló-Ortuño, M. Teresa
description The epithelial-to-mesenchymal transition (EMT) is a biological process in which a non-motile epithelial cell changes to a mesenchymal state with invasive capacities. However, the EMT program is involved in both physiological and pathological processes. Cancer-associated EMT is known to contribute to increase invasiveness and metastasis, resistance to therapies, and generation of cell populations with stem cell-like characteristics and therefore is deeply involved in tumor progression. This process is finely orchestrated by multiple signaling pathways and regulatory transcriptional networks. The hallmark of EMT is the loss of epithelial surface markers, mainly E-cadherin, and the acquisition of mesenchymal phenotype. These events can be mediated by EMT transcription factors which can cooperate with several enzymes to repress the E-cadherin expression and regulate EMT at the epigenetic and post-translational level. A growing body of evidence indicates that cancer cells can reside in various phenotypic states along the EMT spectrum, where cells can jointly retain epithelial traits with mesenchymal ones. This type of phenotypic plasticity endows cancer cells with tumor-initiating potential. The identification of the signaling pathways and modulators that lead to activation of EMT programs during these disease processes is providing new insights into the plasticity of cellular phenotypes and possible therapeutic interventions.
doi_str_mv 10.1007/s12032-017-0980-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1904208430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1904208430</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-42f067ddf9673215a7ef22f0f9663bb228390e9f875a4f1f34fe52f1b2945a943</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMotlZ_gBsZcOMmevOaSZYi9QEFNwruQmaatFPmUZPMov_elKkigqsk5373nHAQuiRwSwCKu0AoMIqBFBiUBCyP0JQIoTBh5OM43ZlIE5HDBJ2FsAGgRFB1iiZUJjGXdIrUfFvHtW1q0-DY49YG21XrXWuaLHrThTrWfZfVXRaHtvfZ1vcrb0NI4jk6caYJ9uJwztD74_zt4RkvXp9eHu4XuOJMRsypg7xYLp3KC5byTWEdTVp656wsKZVMgVVOFsJwRxzjzgrqSEkVF0ZxNkM3o2_K_hxsiLqtQ2WbxnS2H4ImCjgFyRkk9PoPuukH36Xf7SkmoZAqTxQZqcr3IXjr9NbXrfE7TUDve9Vjrzr1qve9apl2rg7OQ9na5c_Gd5EJoCMQ0qhbWf8r-l_XLygngY0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1903807896</pqid></control><display><type>article</type><title>Epithelial-to-mesenchymal transition in tumor progression</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Prieto-García, Elena ; Díaz-García, C. Vanesa ; García-Ruiz, Inmaculada ; Agulló-Ortuño, M. Teresa</creator><creatorcontrib>Prieto-García, Elena ; Díaz-García, C. Vanesa ; García-Ruiz, Inmaculada ; Agulló-Ortuño, M. Teresa</creatorcontrib><description>The epithelial-to-mesenchymal transition (EMT) is a biological process in which a non-motile epithelial cell changes to a mesenchymal state with invasive capacities. However, the EMT program is involved in both physiological and pathological processes. Cancer-associated EMT is known to contribute to increase invasiveness and metastasis, resistance to therapies, and generation of cell populations with stem cell-like characteristics and therefore is deeply involved in tumor progression. This process is finely orchestrated by multiple signaling pathways and regulatory transcriptional networks. The hallmark of EMT is the loss of epithelial surface markers, mainly E-cadherin, and the acquisition of mesenchymal phenotype. These events can be mediated by EMT transcription factors which can cooperate with several enzymes to repress the E-cadherin expression and regulate EMT at the epigenetic and post-translational level. A growing body of evidence indicates that cancer cells can reside in various phenotypic states along the EMT spectrum, where cells can jointly retain epithelial traits with mesenchymal ones. This type of phenotypic plasticity endows cancer cells with tumor-initiating potential. The identification of the signaling pathways and modulators that lead to activation of EMT programs during these disease processes is providing new insights into the plasticity of cellular phenotypes and possible therapeutic interventions.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-017-0980-8</identifier><identifier>PMID: 28560682</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cadherins ; Cancer ; Cell Transformation, Neoplastic - pathology ; Drug Resistance, Neoplasm ; Epithelial-Mesenchymal Transition ; Gene Expression Regulation, Neoplastic ; Hematology ; Humans ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Neoplastic Stem Cells ; Oncology ; Pathology ; Review Article</subject><ispartof>Medical oncology (Northwood, London, England), 2017-07, Vol.34 (7), p.122-122, Article 122</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Medical Oncology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-42f067ddf9673215a7ef22f0f9663bb228390e9f875a4f1f34fe52f1b2945a943</citedby><cites>FETCH-LOGICAL-c438t-42f067ddf9673215a7ef22f0f9663bb228390e9f875a4f1f34fe52f1b2945a943</cites><orcidid>0000-0002-7617-6681</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-017-0980-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-017-0980-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28560682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prieto-García, Elena</creatorcontrib><creatorcontrib>Díaz-García, C. Vanesa</creatorcontrib><creatorcontrib>García-Ruiz, Inmaculada</creatorcontrib><creatorcontrib>Agulló-Ortuño, M. Teresa</creatorcontrib><title>Epithelial-to-mesenchymal transition in tumor progression</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>The epithelial-to-mesenchymal transition (EMT) is a biological process in which a non-motile epithelial cell changes to a mesenchymal state with invasive capacities. However, the EMT program is involved in both physiological and pathological processes. Cancer-associated EMT is known to contribute to increase invasiveness and metastasis, resistance to therapies, and generation of cell populations with stem cell-like characteristics and therefore is deeply involved in tumor progression. This process is finely orchestrated by multiple signaling pathways and regulatory transcriptional networks. The hallmark of EMT is the loss of epithelial surface markers, mainly E-cadherin, and the acquisition of mesenchymal phenotype. These events can be mediated by EMT transcription factors which can cooperate with several enzymes to repress the E-cadherin expression and regulate EMT at the epigenetic and post-translational level. A growing body of evidence indicates that cancer cells can reside in various phenotypic states along the EMT spectrum, where cells can jointly retain epithelial traits with mesenchymal ones. This type of phenotypic plasticity endows cancer cells with tumor-initiating potential. The identification of the signaling pathways and modulators that lead to activation of EMT programs during these disease processes is providing new insights into the plasticity of cellular phenotypes and possible therapeutic interventions.</description><subject>Cadherins</subject><subject>Cancer</subject><subject>Cell Transformation, Neoplastic - pathology</subject><subject>Drug Resistance, Neoplasm</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neoplastic Stem Cells</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Review Article</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kEtLAzEUhYMotlZ_gBsZcOMmevOaSZYi9QEFNwruQmaatFPmUZPMov_elKkigqsk5373nHAQuiRwSwCKu0AoMIqBFBiUBCyP0JQIoTBh5OM43ZlIE5HDBJ2FsAGgRFB1iiZUJjGXdIrUfFvHtW1q0-DY49YG21XrXWuaLHrThTrWfZfVXRaHtvfZ1vcrb0NI4jk6caYJ9uJwztD74_zt4RkvXp9eHu4XuOJMRsypg7xYLp3KC5byTWEdTVp656wsKZVMgVVOFsJwRxzjzgrqSEkVF0ZxNkM3o2_K_hxsiLqtQ2WbxnS2H4ImCjgFyRkk9PoPuukH36Xf7SkmoZAqTxQZqcr3IXjr9NbXrfE7TUDve9Vjrzr1qve9apl2rg7OQ9na5c_Gd5EJoCMQ0qhbWf8r-l_XLygngY0</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Prieto-García, Elena</creator><creator>Díaz-García, C. Vanesa</creator><creator>García-Ruiz, Inmaculada</creator><creator>Agulló-Ortuño, M. Teresa</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7617-6681</orcidid></search><sort><creationdate>20170701</creationdate><title>Epithelial-to-mesenchymal transition in tumor progression</title><author>Prieto-García, Elena ; Díaz-García, C. Vanesa ; García-Ruiz, Inmaculada ; Agulló-Ortuño, M. Teresa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-42f067ddf9673215a7ef22f0f9663bb228390e9f875a4f1f34fe52f1b2945a943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cadherins</topic><topic>Cancer</topic><topic>Cell Transformation, Neoplastic - pathology</topic><topic>Drug Resistance, Neoplasm</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neoplastic Stem Cells</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prieto-García, Elena</creatorcontrib><creatorcontrib>Díaz-García, C. Vanesa</creatorcontrib><creatorcontrib>García-Ruiz, Inmaculada</creatorcontrib><creatorcontrib>Agulló-Ortuño, M. Teresa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prieto-García, Elena</au><au>Díaz-García, C. Vanesa</au><au>García-Ruiz, Inmaculada</au><au>Agulló-Ortuño, M. Teresa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epithelial-to-mesenchymal transition in tumor progression</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>34</volume><issue>7</issue><spage>122</spage><epage>122</epage><pages>122-122</pages><artnum>122</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><abstract>The epithelial-to-mesenchymal transition (EMT) is a biological process in which a non-motile epithelial cell changes to a mesenchymal state with invasive capacities. However, the EMT program is involved in both physiological and pathological processes. Cancer-associated EMT is known to contribute to increase invasiveness and metastasis, resistance to therapies, and generation of cell populations with stem cell-like characteristics and therefore is deeply involved in tumor progression. This process is finely orchestrated by multiple signaling pathways and regulatory transcriptional networks. The hallmark of EMT is the loss of epithelial surface markers, mainly E-cadherin, and the acquisition of mesenchymal phenotype. These events can be mediated by EMT transcription factors which can cooperate with several enzymes to repress the E-cadherin expression and regulate EMT at the epigenetic and post-translational level. A growing body of evidence indicates that cancer cells can reside in various phenotypic states along the EMT spectrum, where cells can jointly retain epithelial traits with mesenchymal ones. This type of phenotypic plasticity endows cancer cells with tumor-initiating potential. The identification of the signaling pathways and modulators that lead to activation of EMT programs during these disease processes is providing new insights into the plasticity of cellular phenotypes and possible therapeutic interventions.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28560682</pmid><doi>10.1007/s12032-017-0980-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7617-6681</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1357-0560
ispartof Medical oncology (Northwood, London, England), 2017-07, Vol.34 (7), p.122-122, Article 122
issn 1357-0560
1559-131X
language eng
recordid cdi_proquest_miscellaneous_1904208430
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Cadherins
Cancer
Cell Transformation, Neoplastic - pathology
Drug Resistance, Neoplasm
Epithelial-Mesenchymal Transition
Gene Expression Regulation, Neoplastic
Hematology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Neoplastic Stem Cells
Oncology
Pathology
Review Article
title Epithelial-to-mesenchymal transition in tumor progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epithelial-to-mesenchymal%20transition%20in%20tumor%20progression&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Prieto-Garc%C3%ADa,%20Elena&rft.date=2017-07-01&rft.volume=34&rft.issue=7&rft.spage=122&rft.epage=122&rft.pages=122-122&rft.artnum=122&rft.issn=1357-0560&rft.eissn=1559-131X&rft_id=info:doi/10.1007/s12032-017-0980-8&rft_dat=%3Cproquest_cross%3E1904208430%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1903807896&rft_id=info:pmid/28560682&rfr_iscdi=true